【レポートの概要(一部)】
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pertussis Overview 10
Therapeutics Development 11
Pipeline Products for Pertussis – Overview 11
Pipeline Products for Pertussis – Comparative Analysis 12
Pertussis – Therapeutics under Development by Companies 13
Pertussis – Therapeutics under Investigation by Universities/Institutes 16
Pertussis – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Pertussis – Products under Development by Companies 21
Pertussis – Products under Investigation by Universities/Institutes 23
Pertussis – Companies Involved in Therapeutics Development 24
Beijing Minhai Biotechnology Co., Ltd 24
Beijing Tiantan Biological Products Co., Ltd. 25
Bharat Biotech International Limited 26
Biological E. Limited 27
Daiichi Sankyo Company, Limited 28
DBV Technologies S.A. 29
Green Cross Corporation 30
Indian Immunologicals Limited 31
LG Life Sciences, Ltd. 32
NanoBio Corporation 33
Novartis AG 34
Panacea Biotec Limited 35
Sanofi 36
Sanofi Pasteur SA 37
Serum Institute of India Limited 38
Sinovac Biotech Ltd. 39
Synthetic Biologics, Inc. 40
Takeda Pharmaceutical Company Limited 41
Zydus Cadila Healthcare Limited 42
Pertussis – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
diphtheria + pertussis + tetanus vaccine – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diphtheria + pertussis + tetanus vaccine – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
diphtheria + tetanus + pertussis (acellular) vaccine – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
diphtheria + tetanus+ pertussis vaccine – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
diptheria + tetanus + pertussis (whole-cell) vaccine – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DTaP Vaccine – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-3111A – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
pertussis (acellular) vaccine – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pertussis (acellular) vaccine – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pertussis (whole-cell) vaccine – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pertussis + hepatitis B vaccine – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
pertussis vaccine – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pertussis vaccine – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pertussis vaccine – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pertussis vaccine – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pertussis vaccine – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Recombinant BCG – Pertussis Vaccine – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SYN-005 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TAK-361S – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
tetanus + diphtheria + pertussis (acellular) vaccine – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
VN-0103 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Pertussis – Recent Pipeline Updates 86
Pertussis – Dormant Projects 88
Pertussis – Product Development Milestones 90
Featured News & Press Releases 90
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 90
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 90
Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 91
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 92
Apr 23, 2014: Synthetic Biologics’ Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic 92
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 93
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 94
Feb 22, 2013: Sanofi Pasteur Announces EMA’s CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 95
Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough 96
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 96
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99
【レポート販売概要】
■ タイトル:百日咳(Pertussis)の治療薬パイプライン動向(2015年上半期版)■ 英文:Pertussis - Pipeline Review, H1 2015
■ 発行日:2015年1月22日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6035IDB
■ 調査対象地域:グローバル
- コクサッキーウイルス検査の世界市場2015The report presents a detailed analysis of the Coxsackievirus diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Coxsackievirus definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- 世界の商用航空機用座席市場動向(2012-2016)TechNavio's analysts forecast the Global Commercial Aircraft Seating market to grow at a CAGR of 5.56 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for economy class seats. The market has also been witnessing the growth of wide body aircraft fleet. However, complex regulatory requirements could pose a challenge to the growth o …
- 発酵成分の世界市場予測(~2022):アミノ酸、有機酸、バイオガス、ポリマー(ポリサッカライド/キサンタン)、ビタミン、工業用酵素The global fermented ingredients market has grown exponentially in the last few years. The market size is projected to reach USD 35.63 Billion by 2022, at a CAGR of around 9.0% from 2017. Factors such as growth in bio-ethanol & antibiotics industry and rise in awareness among consumers toward quality fermented food ingredients are some of the major drivers of this market. Emerging countries such a …
- Kビューティー製品の世界市場:製品タイプ別(シートマスク、クレンザー、保湿剤、化粧品、その他)、エンドユーザー別(男性、女性)、流通経路別(オンライン小売、スーパーマーケット/ハイパーマーケット、専門/モノブランドストア)Despite the dominance of western cosmetics giants, the South Korean brands are gradually setting novel standards of beauty, driven especially by the global popularity of K-pop. A large number of people, irrespective of their gender, are capitalizing on beauty products originated from South Korea. K-beauty products are manufactured using exceptional ingredients, which result into unique and desirab …
- Opium (Opioid) Addiction:グローバル臨床試験レビューH2, 2013Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial num …
- 教育機関向けプロジェクターのアメリカ市場2016-2020About Education Projectors in the US Despite the country's financial crisis, the education industry has remained resilient and recorded significant milestones by pioneering the invention and implementation of various education technology products. During that period, the US government introduced several government initiatives aimed at modernizing the education system and enhancing the learning env …
- 閉塞性動脈疾患(Occlusive Arterial Disease (OAD)):治療薬のグローバル治験動向(2014年下半期)Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Occlusive Arterial Disease (OAD) Global Clinical Trials Review, H2, 2014" provides data on the Occlusive Arterial Disease (OAD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Occlusive Arterial Disease (OAD). It inclu …
- フォレンジック技術の世界市場:DNAフィンガープリント技術、フォレンジック分析技術About Forensic Technology Forensic technology is an important part of criminal investigations and is used for the analysis, identification, and evaluation of physical evidence gathered from a crime scene. Law enforcement agencies and the legal sector are the major end-users of this technology as it is helpful for them to solve cases. The increased acceptance of technology, especially DNA testing t …
- 鼻炎(Rhinitis):世界の治験レビュー2014年下半期版Rhinitis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Rhinitis Global Clinical Trials Review, H2, 2014" provides data on the Rhinitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rhinitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
- EP Petroecuador:石油・ガスバリューチェーン分析レポート2013EP Petroecuador Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "EP Petroecuador" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “EP Petroecuador”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the compan …
- 院外感染性肺炎(Community Acquired Pneumonia)の治療薬パイプライン動向(2015年上半期版)Community Acquired Pneumonia - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H1 2015’, provides an overview of the Community Acquired Pneumonia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, thera …
- 世界の旅客情報システム市場動向及び予測(2014 – 2019)Passenger information systems are the solutions from IT vendors to the transport service providers which helps these operators to provide real time scheduling information to the passengers. These solutions act as a medium for interaction between transport service providers and the passengers. In this report passenger information systems refer to the IT solutions and systems which are used to provi …
- 疣贅性癌(Verrucous Carcinoma):グローバル臨床試験レビュー(2014年上半期)Verrucous Carcinoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Verrucous Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Verrucous Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Verrucous Carcinoma. It includes an overview of the trial numbers and their recru …
- 血行動態モニタリング装置(医療機器)のグローバル新興国市場(2012-2018)BRICSS Hemodynamic Monitoring Devices market value is expected to reach US$281 million by 2016, primarily supported by the product types - Cardiac Output Monitoring Devices and Pulmonary Artery Catheters. China accounts for nearly 24% of the market share and India claims more than 24%. In terms of CAGR, India is the fastest growing region while China and South Korea are just behind. Among the prod …
- ノイズ対策部品の世界市場2017-2021:PCBシールド、ガスケット、EMIフィルタ、積層体/テープAbout Noise Suppression Components Noise is a fluctuation in an electrical signal exhibited by all the electronic circuits. Noise produced by electronic devices varies as it is produced by several different effects. For effective noise suppression in electronic equipment, the design engineers should require a good understanding of the different types of EMI suppression filters and the features so …